Law Firms Urge Telix Investors Ahead of Lead‑Plaintiff Deadline in Securities Class Action

Overview

• A securities class action has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) alleging violations of Sections 10(b) and 20(a) and Rule 10b‑5.
• Complaints assert Telix overstated progress on prostate cancer therapeutics as well as the reliability of its third‑party supply and manufacturing partners.
• Investor notices reference an SEC subpoena into prostate therapeutics disclosures and an FDA Complete Response Letter citing CMC issues and Form 483 observations.
• Hagens Berman reports the final regulatory disclosure precipitated a 21% drop in Telix American Depositary Shares, contributing to alleged investor losses.
• DJS Law Group, Berger Montague, Levi & Korsinsky, and Hagens Berman are soliciting shareholders who bought during February 21 through August 28, 2025 to consider participation or lead‑plaintiff roles.